2022
DOI: 10.3390/biomedicines10092320
|View full text |Cite
|
Sign up to set email alerts
|

The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management

Abstract: Several studies have indicated lipid metabolism alterations during COVID-19 infection, specifically a decrease in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) concentrations and an increase in triglyceride (TG) levels during the infection. However, a decline in triglycerides can also be observed in critical cases. A direct correlation can be observed between a decrease in serum cholesterol, HDL-C, LDL-C and TGs, and the severity of the disease; these laboratory findings can serve as potenti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 96 publications
0
7
0
Order By: Relevance
“…As shown by the present case, hepatic injury may result from SARS-CoV-2 infection as well as from interactions with hypolipidemic drugs administered in HoFH and their up-titration due to rebound increases after infection 18 , 19 . Based on current literature, suggesting that liver stiffness may precipitate after SARS-CoV-2 infection 19 , and on our observations, it would be reasonable for HoFH patients after SARS-CoV-2 infection to be more closely monitored than already recommended for liver function and signs of fibrosis or steatosis particularly when considering up-titration of lomitapide.…”
Section: Discussionmentioning
confidence: 55%
“…As shown by the present case, hepatic injury may result from SARS-CoV-2 infection as well as from interactions with hypolipidemic drugs administered in HoFH and their up-titration due to rebound increases after infection 18 , 19 . Based on current literature, suggesting that liver stiffness may precipitate after SARS-CoV-2 infection 19 , and on our observations, it would be reasonable for HoFH patients after SARS-CoV-2 infection to be more closely monitored than already recommended for liver function and signs of fibrosis or steatosis particularly when considering up-titration of lomitapide.…”
Section: Discussionmentioning
confidence: 55%
“…Interestingly, some classical exosomal markers such as Annexin-V and RAB7 (albeit in opposite directions), as well as some presumably contaminating proteins such as Calnexin showed significantly deregulated levels in circulating EVs from the COVID-19 groups. Because the method we employed for EV purification has been demonstrated to produce highly enriched EV preparations, we reasoned that the presence of specific proteins generally considered to be contaminating proteins may underlie relevant biological changes of EV composition and/or EV corona, induced by COVID-19 and possibly viral infections in general [35] , [36] , [37] . However, as a limitation of our study, we are not able to confirm this because we do not have a comparable control group exempted of viral infection.…”
Section: Discussionmentioning
confidence: 99%
“…Benefits and risks of common medications used in metabolic syndrome management in the setting of COVID-19 are an area of intense research and discussion and have been reviewed in detail elsewhere [68] , [69] , [70] , [71*] , [72] , [73] . Data from meta-analyses [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , observational studies [25] and randomized controlled trials [84] , [85*] , [86] , [87] , [88*] , [89] have emerged while several studies are on-going.…”
Section: Preventing and Managing Covid-19 In People With Metabolic Sy...mentioning
confidence: 99%